COLORADO SPRINGS, Colo., Jan. 6 /PRNewswire/ — Biosyntrx, a privately held eye-care-focused biotechnology company, leads the eye-specific supplement industry with cost-effective evidence-based formulas, with particular attention paid to formulation design and raw ingredient selection.
Macula Complete, the most inclusive and best-selling full-spectrum vitamin/mineral/antioxidant multiple designed for optimal eye and body health was reformulated to increase Vitamin D from 1,200 IU to 2,000 IU of Vitamin D3 to address the Vitamin D deficiency epidemic, a biochemical-balance of all eight parts of Vitamin E tocopherols and tocotrienols, including DeltaGold tocotrienols, 100 mg of Trans-Resveratrol, 100 mg Green Tea, as well as the 200 mg of Acetyl-L-Carnitine, 30 mg of CoQ10, and 150 mg of Lipoic Acid for optimal mitochondrial, antiangeogenic, anti-inflammatory activity and cellular delivery.
“Our team of thought-leading ophthalmologists, optometrists, biochemists and molecular biologists are committed to developing innovative eye and body health nutritional formulations that reflect the most current nutrition science, improved patient compliance, and meets the most stringent science-based regulatory and manufacturing standards,” said Biosyntrx CEO/Chief Research Officer, Ellen Troyer, MT, MA, of Colorado Springs, CO.
The Biosyntrx Scientific Advisory Board includes well-known leaders in medicine, science and nutrition such as: Richard Lindstrom, MD, Minneapolis, MN, Jerre Freeman, MD, Memphis, TN, Robert H. Osher, MD, Cincinnati, OH, Betty Kamen, PhD, San Francisco, CA, Marguerite B. McDonald, MD, Long Island, NY, Randall Olson, MD, Salt Lake City, UT, John W. Lahr, OD, Cincinnati, OH, Hal Bohlman, OD, Mountain Home, TN, Stephen Slade, MD, Houston, TX, Bill Rafferty, OD, Durham, NC, Jack Holladay, MD, Houston, TX, Roger Steinert, MD, Irvine, CA, Paul Sternberg, MD, Nashville, TN, Stephen Whiting, PhD, San Diego, CA, Burton Goldberg, PhD, Tiburon, CA and Marsha Raanan, MS, Chicago, IL. www.biosyntrx.com